Pabla N., and Sparreboom A. Proton pump inhibitors may cause a decline in eGFR by inhibiting OCT2-dependent creatinine secretion. J. Am. Soc. Nephrol. (in press), 2024 (IF 10.121)
Elgamal O.A., Fobare S., Vibhute S., Mehmood A., Vroom D.C., Johnson M.L., Stearns B., Lerma J.R., Truxall J., Stahl E., Carmichael B., Orwick S.J, Mims A.S., Curran E., Santhanam R., Tridandapani S., Phelps M.A., Zhiliang Xie Z., Coss C.C., Baker S.D., Patrick J., Ezzell J.K., Rai J., Pan J., Rai S.N., Stillwell C., Wunderlich M., Abdulrahim M., Goodwin T.E., Hilinski G., Bennett C.E., E., and Byrd J.C. Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia. JCI Insight 22;9(8):e173646, 2024Link
Galetin A., Brouwer K.L.R., Tweedie D., Yoshida K., Sjöstedt N., Chu X., Evers R., Hafey M.J., Lai Y., Matsson P., Riselli A., Shen H., Sparreboom A., Varma M.V.S., Yang J., Yang X., Yee S.W., Zamek-Gliszczynski M.J., Zhang L., and Giacomini K.M. Membrane transporters in drug development and as key determinants of precision medicine; an update from the International Transporter Consortium Nat. Rev. Drug Discov. 23(4): 255-280, 2024. Link (IF 120.1)
Anabtawi N., Drabison T., Jin Y., Eisenmann E.D., Sparreboom A., Govindarajan R., Baker S.D., and Ahmed E. Pharmacokinetic assessment of low dose decitabine in combination therapies: development and validation of a sensitive UHPLC-MS/MS method for murine plasma analysis JChromatogr. B. 1242: 124209, 2024 Link (IF 3.205)
Taheri H., Jin Y., Hu P., Ahmed E., Li Y., Sparreboom A., and Hu S. Quantification of the aromatase inhibitor letrozole and its carbinol metabolite in mouse plasma by UHPLC-MS/MS J Chromatogr. B. 1238: 124106, 2024 Link (IF 3.205)
Buck S, Talebi Z, Drabison T, Jin Y, Gibson A, Hu P, de Bruijn P, Hu S, van Weerden W, Koolen S, De Wit R, Sparreboom A, Mathijssen R, Eisenmann E. Darolutamide does not interfere with OATP-mediated uptake of docetaxel. Int J of Cancer. 155(2): 314-323, 2024. Link(IF 7.396)
Li Y, Drabison T, Kazuki Y, Kobayashi K, Fujita K, Xu X,Jin Y, Ahmed E, Li J, Eisenmann E,Baker SD, Cavaletti G, Sparreboom A, Hu S. Vincristine Disposition and Neurotoxicity in Humanized CYP3A5 Mice. Drug Metabolism and Disposition. 52(2):80-85. Link (IF 3.922)
2023
Eisenmann E.A., and Sparreboom A. Unique cabozantinib dosing considerations in people living with HIV and cancer. Clin. Cancer Res. 29(24): 4999-5001, 2023. Link (IF 11.1)
Talebi Z., Garrison D.A., Eisenmann E.D., Parmar K., Shapiro G.I., Rudek M.A., Sparreboom A., and Jin Y. Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method. Heliyon 9(11) e20972, 2023 Link (IF 4.0)
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O’Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 May 20;41(15):2701-2705. Link (IF, 50.739)
Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD*, Byrd JC*. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 Aug 22;7(16):4671-4675. Link *Co-senior authors (IF, 7.642)
Kagan AB, Garrison DA, Anders NM, Webster JA, Baker SD, Yegnasubramanian S, Rudek MA. DNA methyltransferase inhibitor exposure-response: Challenges and opportunities. Clin Transl Sci. 2023 Aug;16(8):1309-1322. Link (IF, 4.516)
Li Y, Drabison T, Nepal M, Ho RH, Leblanc AF, Gibson AA, Jin Y, Yang W, Huang KM, Uddin ME, Chen M, DiGiacomo DF, Chen X, Razzaq S, Tonniges JR, McTigue DM, Mims AS, Lustberg MB, Wang Y, Hummon AB, Evans WE, Baker SD, Cavaletti G, Sparreboom A, Hu S. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy. JCI Insight. 2023 Jul 24;8(14):e164646. Link (IF, 8.04)
Persaud AK, Bernier MC, Massey MA, Agrawal S, Kaur T, Nayak D, Xie Z, Weadick B, Raj R, Hill K, Abbott N, Joshi A, Anabtawi N, Bryant C, Somogyi A, Cruz-Monserrate Z, Amari F, Coppola V, Sparreboom A, Baker SD, Unadkat JD, Phelps MA, Govindarajan R. Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice. Nat Commun. 2023 Jun 1;14(1):3175. Link (IF, 16.6)
Talebi Z, Jin Y, Baker SD, Addison D, Sparreboom A. Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 May 1;1222:123699. Link (IF, 3.318)
2022
Anabtawi N, Drabison T, Hu S, Sparreboom A, Talebi Z. The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):459-468. Link (IF, 4.481)
Anderson JA, Huang KM, Lustberg MB, Sparreboom A, Hu S. Solute carrier transportome in chemotherapy-induced adverse drug reactions. Rev Physiol Biochem Pharmacol. 2022;183:177-215. Link (IF, 5.545)
Brouwer KLR, Evers R, Hayden E, Hu S, Li CY, Meyer zu Schwabedissen HE, Neuhoff S, Oswald S, Piquette-Miller M, Saran C, Sjöstedt N, Sprowl JA, Stahl SH, Yue W. Regulation of drug transport proteins – from mechanisms to clinical impact: A white paper on behalf of the international transporter consortium. Clin Pharmacol Ther. 2022 Sep;112(3):461-484. Link (IF, 6.903)
Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD*, Blaser BW*. BMX kinase mediates gilteritinib gesistance in FLT3-mutated AML through microenvironmental factors. Blood Adv. 2022 Sep 13;6(17):5049-5060. Link *Co-senior authors (IF, 6.5)
Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim J-G, Sparreboom A, Savona MR, Mims AS, Baker SD. Interaction of antifungal drugs with CYP3A-and OATP1B-mediated venetoclax elimination. Pharmaceutics. 2022 Mar 23;14(4):694. Link (IF, 6.29)
Eisenmann ED, Stromatt JC, Fobare S, Huang KM,Buelow DR, Orwick S, Jeon JY, Weber RH, Larsen B, Mims AS, Hertlein E, Byrd JC, Baker SD. TP-0903 Is active in preclinical models of acute myeloid leukemia with TP53 mutation/deletion. Cancers. 2022 Dec 21;15(1):29. Link (IF, 6.32)
Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED. Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B. Molecules. 2022 Oct 12;27(20):6815. Link (IF, 4.927)
Gartrell J, Panetta JC, Baker SD, Chen YL, Hawkins DS, Ostrenga A, Scharschmidt TJ, Spunt SL, Wang D, Weiss AR. The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321. Cancer Chemother Pharmacol. 2022 Apr;89(4):551-557. Link (IF, 3.581)
Hafey MJ, Aleksunes LM, Bridges CC, Brouwer KR, Chien H-C, Leslie EM, Hu S, Li Y, Shen J, Sparreboom A, Sprowl JA, Tweedie D, Lai Y. Transporters and toxicity: insights from the International Transporter Consortium workshop 4. Clin Pharmacol Ther. 2022 Sep;112(3):527-539. Link (IF, 6. 903)
Hove VN, Anderson K, Hayden ER, Pasquariello KZ, Gibson AA, Shen S, Qu J, Jin Y, Miecznikowski JC, Hu S, Sprowl JA. Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake. Mol Pharmacol. 2022 Jun;101(6):381-389. Link (IF, 4.436)
Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui C-H, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD. Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication. Clin Cancer Res. 2022 Jun 13;28(12):2536-2546. Link (IF,13.8)
Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S. Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Nov 1;1210:123437. Link (IF, 3.205)
Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S. A Metabolomics approach for predicting OATP1B-Type transporter-mediated drug-drug interaction liabilities. Pharmaceutics. 2022 Sep 13;14(9):1933. Link (IF, 6.29)
Nepal MR, Taheri H, Li Y, Uddin ME, Jin Y, DiGiacomo DF,Gibson AA, Lustberg MB, Hu S, Sparreboom A. Targeting OCT2 with duloxetine to prevent oxaliplatin-induced peripheral neurotoxicity. Cancer Res Commun. 2022 Nov;2(11):1334-1343. Link. (IF, 2.0)
Stephens D, Ying H, Stark A, Walker J, Canfield D, Cempre C, Baker S, Boyu H, Shah H, Vadeboncoeur R, Rogers K, Bhat S, Jaglowski S, Lockman H, Lapalombella R, Byrd JC, Woyach J. Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. Clin Cancer Res. 2022 Aug 2;28(15):3242-3247. Link (IF, 13.8)
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in targeted therapy and supportive care therapies for cancer. Methods Mol Biol. 2022;2547:47-61. Link (IF, 1.37)
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in cytotoxic chemotherapy of cancer. Methods Mol Biol. 2022;2547:63-94. Link (IF, 1.37)
Uddin ME, Eisenmann ED, Huang KM, Garrison DA,Talebi Z, Gibson AA, Jin Y,Nepal M, Bonilla IM, Fu Q, Miller A, Tarasovc M, Jay CE, Cui X, Einolf HJ, Pelise RM, Smith S, Radwanski P, Sweet DH, König J, Fromm MF, Carnes CA, Hu S, Sparreboom A. MATE1 deficiency exacerbates dofetilide-induced proarrhythmia. Int J Mol Sci. 2022 Aug 3;23(15):8607. Link (IF, 6.208)